Literature DB >> 8996432

Epithelial ovarian carcinoma.

G B Kristensen1, C Tropé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8996432     DOI： 10.1016/S0140-6736(96)06071-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  26 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.

Authors:  Hakan Karagol; Pinar Saip; Kazim Uygun; Murat Caloglu; Yesim Eralp; Faruk Tas; Adnan Aydiner; Erkan Topuz
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  The induction of the apoptosis of cancer cell by sonodynamic therapy: a review.

Authors:  Wen-Kun Bai; E Shen; Bing Hu
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer.

Authors:  Inge T A Peters; Carolien van Haaften; J Baptist Trimbos
Journal:  J Gynecol Surg       Date:  2014-10-01

Review 5.  Angiogenesis in epithelian ovarian cancer.

Authors:  E S Bamberger; C W Perrett
Journal:  Mol Pathol       Date:  2002-12

6.  E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.

Authors:  Narasimhan Kothandaraman; Vladimir B Bajic; Pang N K Brendan; Chan Y Huak; Peh B Keow; Khalil Razvi; Manuel Salto-Tellez; Mahesh Choolani
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

Review 7.  Topotecan. A review of its potential in advanced ovarian cancer.

Authors:  R N Brogden; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

8.  BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.

Authors:  Y-K Lee; E Choi; M A Kim; P-G Park; N-H Park; H Lee
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

9.  Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

Authors:  G Smith; M T H Ng; L Shepherd; C S Herrington; C Gourley; M J Ferguson; C R Wolf
Journal:  Br J Cancer       Date:  2012-09-18       Impact factor: 7.640

10.  Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.

Authors:  T Mitamura; H Watari; L Wang; H Kanno; M K Hassan; M Miyazaki; Y Katoh; T Kimura; M Tanino; H Nishihara; S Tanaka; N Sakuragi
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.